Valproic acid treatment attenuates cisplatin-induced kidney injury by suppressing proximal tubular cell damage [0.03%]
丙戊酸治疗通过抑制近端小管细胞损伤来减轻顺铂引起的肾损伤
Toshihiko Yoshioka,Mitsuhiro Goda,Masaya Kanda et al.
Toshihiko Yoshioka et al.
Cisplatin treatment is effective against several types of carcinomas. However, it frequently leads to kidney injury, which warrants effective prevention methods. Sodium valproic acid is a prophylactic drug candidate with a high potential fo...
Japan's COVID-19 treatment strategy: An examination of approved oral medications [0.03%]
日本的新冠肺炎治疗策略——获批口服药物评估报告
Yuka Higuchi,Yudai Kaneda,Tetsuya Tanimoto
Yuka Higuchi
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants [0.03%]
健康志愿者中雾化吸入瑞德西韦的药代动力学、安全性和耐受性
Rita Humeniuk,Kavita Juneja,Shuguang Chen et al.
Rita Humeniuk et al.
Intravenous remdesivir (RDV) is US Food and Drug Administration-approved for hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV undergoes intracellular metabolic activation to form the active triphosphate, GS-44...
Randomized Controlled Trial
Clinical and translational science. 2023 Nov;16(11):2276-2288. DOI:10.1111/cts.13627 2023
Effects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: A randomized, placebo- and positive-controlled thorough QT study in healthy individuals [0.03%]
氯苯達唑及其代謝物對校正心率的QT間期的影響：健康受試者的徹底QT研究
William T Prince,Vinay Kumar Venishetty,Jean Lecot et al.
William T Prince et al.
Triclabendazole is an effective and well-tolerated treatment for human fascioliasis. A placebo- and positive-controlled, four-sequence by four-period crossover study was conducted in 45 healthy participants to assess the effect of therapeut...
Randomized Controlled Trial
Clinical and translational science. 2023 Oct;16(10):1758-1767. DOI:10.1111/cts.13564 2023
Genomics and transcriptomic alterations of the glutamate receptors in acute myeloid leukemia [0.03%]
急性髓系白血病中的谷氨酸受体基因组和转录组改变
Amani Alqahtani,Mengxi Wang,Mimi Lou et al.
Amani Alqahtani et al.
Glutamine and glutamate have been widely explored as potential therapeutic targets in acute myeloid leukemia (AML). In addition to its bioenergetic role in leukemia cell proliferation, L-glutamate is a neurotransmitter that acts on glutamat...
Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model [0.03%]
基于生理学的酶和转运体药动学网络相互作用模型预测ziritaxestat药物相互作用
Jeremy Perrier,Virginie Gualano,Eric Helmer et al.
Jeremy Perrier et al.
Ziritaxestat, an autotaxin inhibitor, was under development for the treatment of idiopathic pulmonary fibrosis. It is a substrate of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein and a weak inhibitor of the CYP3A4 and OATP1B1 pathways. We...
Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment [0.03%]
BMS-986263的药代动力学、安全性和耐受性：健康志愿者和肝功能受损受试者中的HSP47siRNA脂质纳米颗粒的研究
Hisham Qosa,Claudia H M C de Oliveira,Giovanni Cizza et al.
Hisham Qosa et al.
BMS-986263 is a retinoid-conjugated lipid nanoparticle delivering small interfering RNA designed to inhibit synthesis of HSP47 protein, a collagen-specific chaperone protein involved in fibrosis development. This is a phase I, open-label, t...
Magda Wojtara,Emaan Rana,Taibia Rahman et al.
Magda Wojtara et al.
Artificial intelligence (AI) utilization in health care has grown over the past few years. It also has demonstrated potential in improving the efficiency of diagnosis and treatment. Some types of AI, such as machine learning, allow for the ...
Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study [0.03%]
中国成人中重度斑块状银屑病患者secukinumab治疗结局的真实世界多中心回顾性研究
Yangfeng Ding,Wei Li,Xin Guan et al.
Yangfeng Ding et al.
Secukinumab is effective in treating patients with moderate-to-severe plaque psoriasis. However, most studies assessing its effectiveness in routine clinical settings in China are mostly single-center studies with a limited sample size. The...
Multicenter Study
Clinical and translational science. 2023 Oct;16(10):1803-1814. DOI:10.1111/cts.13583 2023
CYP2C19 genotypes and osteoporotic fractures in long-term users of proton pump inhibitors: A hospital-based study [0.03%]
基于医院的长期质子泵抑制剂使用者CYP2C19基因型与骨质疏松性骨折关系的研究
Yi-Ju Liao,Yu-Ting Chen,Tzu-Hung Hsiao et al.
Yi-Ju Liao et al.
Proton pump inhibitors (PPIs) are commonly prescribed medications. The existing data suggest that individuals at a high risk of fractures have been exposed to high doses of PPIs for prolonged durations. CYP2C19 plays a pivotal role in metab...